INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 127 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 2.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $8,000 | +33.3% | 2,525 | 0.0% | 0.00% | – |
| Q3 2019 | $6,000 | +20.0% | 2,525 | +51.8% | 0.00% | – |
| Q2 2019 | $5,000 | -16.7% | 1,663 | +9.0% | 0.00% | – |
| Q1 2019 | $6,000 | 0.0% | 1,525 | 0.0% | 0.00% | – |
| Q4 2018 | $6,000 | -33.3% | 1,525 | 0.0% | 0.00% | – |
| Q3 2018 | $9,000 | -82.7% | 1,525 | -88.5% | 0.00% | -100.0% |
| Q2 2018 | $52,000 | -16.1% | 13,258 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $62,000 | -13.9% | 13,258 | -24.8% | 0.00% | 0.0% |
| Q4 2017 | $72,000 | -12.2% | 17,634 | +35.6% | 0.00% | 0.0% |
| Q3 2017 | $82,000 | -10.9% | 13,008 | +11.4% | 0.00% | -50.0% |
| Q2 2017 | $92,000 | +16.5% | 11,675 | -1.3% | 0.00% | 0.0% |
| Q1 2017 | $79,000 | +8.2% | 11,825 | +11.8% | 0.00% | 0.0% |
| Q4 2016 | $73,000 | -38.7% | 10,575 | -16.6% | 0.00% | -33.3% |
| Q3 2016 | $119,000 | +815.4% | 12,677 | +729.6% | 0.00% | – |
| Q2 2016 | $13,000 | – | 1,528 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |